Filing Flows › Verastem (VSTM) › Guidance & outlook

Verastem (VSTM) guidance and outlook

Verastem's 10-Q filed Nov 5, 2026 makes 12 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 5, 2026

• Our focus is on novel small molecule drugs developed both as monotherapy and in combination, which inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including targeting RAS directly with KRAS G12D inhibition, targeting the pathway downstream with RAF/MEK inhibition, and targeting the parallel pathway that drives resistance with FAK inhibition.
• In April 2026, we branded the trials as the VS-7375 TARGET-D Clinical Trial Program.
• In the TARGET-D 101 Phase 1/2 study, we cleared multiple monotherapy dose levels, including the 1200 mg QD dose with no dose-limiting toxicities (“DLTs”) and no major toxicities.
• We completed targeted enrollment in patients with pancreatic and lung cancer monotherapy cohorts and the colorectal cancer combination cohort with cetuximab in the Phase 1/2 study.
• In the first half of 2026, we initiated three Phase 2 registration-directed trials of VS-7375, our oral KRAS G12D (ON/OFF) inhibitor, dosing the first patients in TARGET-D 201 (PDAC) in June 2026, and both TARGET-D 202 (NSCLC) and TARGET-D 203 (CRC) in July 2026.
• We expect to finance our operations with our existing cash, cash equivalents and investments, through potential future milestones and royalties received pursuant to the Secura APA, through the Note Purchase Agreement, through future product revenues or through other strategic financing opportunities that could include, but are not limited to collaboration agreements, offerings of our equity, or the incurrence of…
• We expect cost of sales - product to increase in relation to product revenues as we deplete these inventories.
• We record expenses related to external research and development services, such as CROs, clinical sites, pass-through fees such as investigator fees, manufacturing organizations and consultants, by project and/or product candidate.
• We use our employee and infrastructure resources in a cross-functional manner across multiple research and development projects.
• Our project costing methodology does not allocate personnel, infrastructure and other indirect costs to specific clinical programs or projects.
• The table below summarizes our direct research and development expenses for our product/ product candidates/ projects and our unallocated research and development costs for the 2026 Quarter and the 2025 Quarter.
• We expect to finance a portion of our business through future potential milestones and royalties received pursuant to the Secura APA.

Verastem's latest quarter

Questions

What does Verastem expect?

Our focus is on novel small molecule drugs developed both as monotherapy and in combination, which inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including targeting RAS directly with KRAS G12D inhibition, targeting the pathway downstream with RAF/MEK inhibition, and targeting the parallel pathway that drives resistance with FAK inhibition. In April 2026, we branded the trials as the VS-7375 TARGET-D Clinical Trial Program. In the TARGET-D 101 Phase 1/2 study, we cleared multiple monotherapy dose levels, including the 1200 mg QD dose with no d

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.